



March 3, 2025

Company Name Alivexis, Inc.  
C E O Suguru Roy Kimura

### **Alivexis Raises \$0.7M USD Series D in Second Close**

News – March 3, 2025 – Alivexis, Inc. (Headquartered in Minato-ku, Tokyo; CEO S. Roy Kimura, “Alivexis”) a preclinical-stage computation-driven drug discovery firm, announces the second closing of its Series D round in the amount of 100M JPY (approximately \$0.7M USD). Investor participating in the second closing is Ohara Pharmaceutical Co., Ltd. (Headquartered in Koga City, Shiga Prefecture; CEO Seiji Ohara). The total amount raised in Series D round is 900M JPY (approximately \$6.0 USD), and Alivexis has raised a total of 6.76B JPY (approximately \$45.0M USD) to date.

Alivexis will use the proceeds to further research and development programs utilizing its cutting-edge computational science-based drug discovery platform “ModBind™”, in addition to accelerating over 10 in-house R&D programs. Alivexis will expand key business strategies in early out-licensing and drug discovery collaboration, with the aim of further increasing its corporate value.

Comment from S. Roy Kimura, Ph.D., Co-founder and CEO:

“We are excited to announce the second closing of our latest funding round by Ohara Pharmaceutical Co., Ltd. Since our last fund-raise, we have successfully licensed our cathepsin C inhibitor program and are currently working together with our partner toward IND submission. We also published a scientific article on the first version of our ModBind™ simulation platform, based on a unique theoretical approach that enables accurate absolute ligand efficacy predictions at ~2000x speeds relative to existing methods. In the next several months, we expect to sign additional licensing partnerships from our portfolio of immunology and oncology R&D programs, as well as additional ModBind™-related alliances and collaborations. We look forward to continuing our mission with our shareholders and partners to accelerate discovery of new medicines for patients and their families in need.”



**About Alivexis, Inc.:**

Name: Alivexis, Inc.

Headquarter: Daiichi Hibiya Building 7F, Shimbashi 1-18-21, Minato-ku, Tokyo 105-0004, Japan

Representative directors: S. Roy Kimura, Ph.D., CEO / Kazuki Ohno, Dr. Eng. COO

Established: August 8, 2016

URL: <https://alivexis.com>

Business Description: A network-based drug discovery company utilizing cutting-edge technologies.

**About Ohara Pharmaceutical Co., Ltd.:**

Name: Ohara Pharmaceutical Co., Ltd.

Headquarter: 121-15 Toriino, Koga-cho, Koga City, Shiga Prefecture 520-3403, Japan

Representative director: Seiji Ohara, CEO

Established: November 5, 1964

URL: <https://www.ohara-ch.co.jp/>

Business Description: Discovery and manufacture of orphan and generic drugs. Focuses on developing new drugs in core therapeutic areas, child cancer, hematologic cancer, CNS and development, manufacturing and marketing of generic drugs. Aims to provide comprehensive healthcare solutions by innovating in treatment, prevention, diagnosis, and aftercare.

<p>Contact Information Business Administration Division info@alivexis.com</p>
---